Epinephrine is under clinical development by VasoDynamics and currently in Phase I for Oral Mucositis. According to GlobalData, Phase I drugs for Oral Mucositis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Epinephrine LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Epinephrine overview
Epinephrine (NG11-2) is under development for the prevention of radiation-induced oral mucositis (RIOM) in head and neck cancer. The drug candidate is administered oro-topically.
VasoDynamics overview
VasoDynamics develops medications for the prevention and treatment of complications of cancer therapy. The company is a young with young-at-heart executives and a shared vision to improve the standard of cancer care globally. It’s pipeline products include NG11 program targeting radiation-induced oral mucositis (RIOM), an inflammation caused in head and neck cancer patients due to radio and chemo therapy; NG12, a topical administration medication for prevention of radiation-induced dermatitis; and NG13 against alopesia (hair loss) caused due to chemotherapy .VasoDynamics is headquartered in Stevenage, Hertfordshire, the UK.
For a complete picture of Epinephrine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
